The effects of N-acetylcysteine on cisplatin induced cardiotoxicity

Bratislava Medical Journal

article

E. E. Gunturk¹  B. Yucel²  I. Gunturk³  C. Yazici⁴  A. Yay⁵  K. Kose⁴ 

[1] Nigde Omer Halisdemir University, Faculty of Medicine, Department of Cardiology;Izmir Konak Public Health Laboratory, Department of Biochemistry;Nigde Omer Halisdemir University, School of Health, Department of Midwifery;Erciyes University, Faculty of Medicine, Department of Biochemistry;Erciyes University, Faculty of Medicine, Department of Histology and Embryology

关键词: rats;    cisplatin;    oxidative stress;    cardiotoxicity;    N-acetylcysteine;   

DOI  :  10.4149/BLL_2019_068

学科分类：医学（综合）

来源: AEPress, s.r.o.

【 摘 要 】

OBJECTIVES: Recent studies reported that oxidative stress is an important mechanism that contributes to cisplatin induced cardiotoxicity. In the present study, the effects of N-acetylcysteine (NAC), which is an antioxidant, on cisplatin induced cardiotoxicity were investigated in a rat model. METHODS: Thirty two rats were separated into 4 equal groups: Control, NAC-250, CP (cisplatin), CP+NAC. Rats in the experimental groups were treated with a single dose of cisplatin intraperitoneally (ip) (10 mg/kg) and NAC (ip, 250 mg/kg) for 3 consecutive days. At the end of the experiment, cardiotoxicity was determined from plasma CK-MB, LDH, cTnI and cardiac myosin light chain-1 (CMLC-1) levels. In the tissue samples, total oxidant capacity (TOC), total antioxidant capacity (TAC), lipid hydroperoxide (ROOH) and thiol levels were measured. The hearts were also analyzed histopathologically. RESULTS: It was determined that cisplatin increased the tissue TOC, ROOH levels and decreased TAC and thiol levels. NAC administration after cisplatin treatment was observed to have ameliorated histological and functional changes in heart. CONCLUSIONS: In conclusion, the results of this experimental study suggested that oxidative stress had a serious effect on cisplatin cardiotoxicity, and NAC could be used as a therapeutic agent in addition to standard cisplatin treatment protocols (Tab. 3, Fig. 1, Ref. 35).

【 授权许可】

CC BY